For more on David Nierengarten’s comments: These 28 biotech startups have attracted the most VC cash, making them prime candidates for an acquisition or IPO
David Nierengarten: Well-Funded VC’s Are Betting Heavily on Biotechs
For more on David Nierengarten’s comments: These 28 biotech startups have attracted the most VC cash, making them prime candidates for an acquisition or IPO